These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 25589625

  • 1. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C.
    Clin Cancer Res; 2015 Mar 15; 21(6):1383-94. PubMed ID: 25589625
    [Abstract] [Full Text] [Related]

  • 2. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E.
    Clin Cancer Res; 2014 Jul 15; 20(14):3775-86. PubMed ID: 24812410
    [Abstract] [Full Text] [Related]

  • 3. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F.
    Clin Cancer Res; 2013 Dec 15; 19(24):6751-65. PubMed ID: 24122793
    [Abstract] [Full Text] [Related]

  • 4. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
    Park HJ, Park JB, Lee SJ, Song M.
    Int J Mol Sci; 2017 Aug 11; 18(8):. PubMed ID: 28800074
    [Abstract] [Full Text] [Related]

  • 5. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G.
    Clin Cancer Res; 2006 Jan 15; 12(2):577-83. PubMed ID: 16428503
    [Abstract] [Full Text] [Related]

  • 6. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S.
    J Thorac Oncol; 2012 Feb 15; 7(2):272-80. PubMed ID: 22089117
    [Abstract] [Full Text] [Related]

  • 7. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
    Jung SA, Lee DH, Moon JH, Hong SW, Shin JS, Hwang IY, Shin YJ, Kim JH, Gong EY, Kim SM, Lee EY, Lee S, Kim JE, Kim KP, Hong YS, Lee JS, Jin DH, Kim T, Lee WJ.
    Free Radic Biol Med; 2016 Jun 15; 95():200-8. PubMed ID: 27012422
    [Abstract] [Full Text] [Related]

  • 8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 9. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA, Trusolino L, Velculescu VE.
    Nature; 2015 Oct 08; 526(7572):263-7. PubMed ID: 26416732
    [Abstract] [Full Text] [Related]

  • 10. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation.
    Ohishi T, Kato Y, Kaneko MK, Ohba SI, Inoue H, Harakawa A, Kawada M.
    Int J Mol Sci; 2020 Aug 21; 21(17):. PubMed ID: 32839411
    [Abstract] [Full Text] [Related]

  • 11. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T.
    Clin Cancer Res; 2015 Jul 01; 21(13):2975-83. PubMed ID: 25838391
    [Abstract] [Full Text] [Related]

  • 12. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.
    Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Köhler J, Paul A, Trarbach T, Schmid KW, Schuler M.
    Oncogene; 2013 Jun 06; 32(23):2873-81. PubMed ID: 22797062
    [Abstract] [Full Text] [Related]

  • 13. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
    Bäumer N, Rehkämper J, Appel N, Terheyden L, Hartmann W, Wardelmann E, Buchholz F, Müller-Tidow C, Berdel WE, Bäumer S.
    PLoS One; 2018 Jun 06; 13(7):e0200163. PubMed ID: 30001368
    [Abstract] [Full Text] [Related]

  • 14. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [Abstract] [Full Text] [Related]

  • 15. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.
    Cancer Res; 2011 Mar 01; 71(5):1520-5. PubMed ID: 21193546
    [Abstract] [Full Text] [Related]

  • 16. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA, De Wever O, Kronenberger P, Van Deun J, Noor A, Singh K, Teugels E, Chen G, Bracke M, De Grève J.
    Oncotarget; 2015 Aug 21; 6(24):20132-44. PubMed ID: 25992771
    [Abstract] [Full Text] [Related]

  • 17. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
    Sato N, Saga Y, Mizukami H, Wang D, Fujiwara H, Takei Y, Machida S, Ozawa K, Suzuki M.
    Oncol Rep; 2012 May 21; 27(5):1336-40. PubMed ID: 22246397
    [Abstract] [Full Text] [Related]

  • 18. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H, Liu Y, Wu K, Luo H, Cui L.
    Cell Commun Signal; 2020 Jul 23; 18(1):115. PubMed ID: 32703218
    [Abstract] [Full Text] [Related]

  • 19. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.
    Clin Cancer Res; 2016 Jul 01; 22(13):3260-7. PubMed ID: 26888827
    [Abstract] [Full Text] [Related]

  • 20. Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.
    Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen M, Wu Q, Xie T, Sui X.
    Theranostics; 2024 Jul 01; 14(14):5443-5460. PubMed ID: 39310106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.